The federal system for approving and regulating drugs is in serious disrepair, and a host of dramatic changes are needed to fix the problem, a blue-ribbon panel of government advisers concluded yesterday in a long-awaited report. The 15 experts drawn from academic and professional organizations were unanimous in endorsing the recommendations.
You can read more about it here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment